A charting look at some of the most followed stocks on the London market, Zak Mir covers
OptiBiotix Health (AIM:OPTI) SlimBiome® wins award at Vitafoods 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes announces that it has won the award for Weight Management Ingredient of the Year at the Vitafoods European tradeshow in Geneva. The award is given to the
OptiBiotix Health (AIM:OPTI) Exclusive manufacturing and supply agreement
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a five year agreement
OptiBiotix Health (AIM:OPTI) Launch of extended range of products at Vitafoods
Launch of extended range of LPLDL® and SlimBiome® products at Vitafoods 2018
OptiBiotix Health (AIM:OPTI) Launch of Slimbiome® in Nutri-bites®
OptiBiotix Health plc (AIM:OPTI) a life sciences business developing compounds to tackle obesity, and high cholesterol, announces the launch of its award-winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”),
OptiBiotix Health (LON:OPTI) SweetBiotix® development: human taste studies
SweetBiotix® development: Results of further human taste studies OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces successful human taste studies in its
OptiBiotix Health (AIM:OPTI) LPLDL® supply agreement with Galenicum
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year supply agreement with Galenicum Special Ingredients, S.L (“Galenicum”) to commercialise products containing OptiBiotix’s cholesterol and blood pressure reducing
OptiBiotix Health (AIM:OPTI) Market launch for LPLDL® capsules in Germany
OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH (“HLH”) have achieved product registration of LPLDL® capsules at IFA GmbH and “Bundesamt für Lebensmittelsicherheit und Verbraucherschutz (BVL)” and commenced commercial
SMALL CAP MOVERS: Corero jumps 11%, ECSC 20% in wake of cyber-security attacks; Proxama tanks after scrapping sale plans
Cyber-security hasn’t strayed too far from the headlines this week thanks to the WannaCry ransomware attack last weekend. Online menace: Cyber-security hasn’t strayed too far from the headlines this week